Parmax Pharma Ltd Stock Price Today (NSE: PARMAX)
Fundamental Score
Parmax Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Parmax Pharma Ltd share price today is ₹66.69, up +1.99% on NSE/BSE as of 17 June 2026. Parmax Pharma Ltd (PARMAX) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹12.83 (Cr). The 52-week high for PARMAX share price is ₹45.87 and the 52-week low is ₹22.60.
Parmax Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Parmax Pharma Ltd share price chart: 24.29% return over the past month. 52-week high ₹45.87, 52-week low ₹22.60.
Parmax Pharma Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹39.00 | ₹41.00 | ₹37.00 | ₹40.67 | 11.38K (Cr) | |
| ₹37.03 | ₹39.00 | ₹37.01 | ₹39.00 | 8.99K (Cr) | |
| ₹36.10 | ₹39.96 | ₹36.10 | ₹37.03 | 1.91K (Cr) | |
| ₹43.00 | ₹43.00 | ₹38.70 | ₹39.96 | 5.35K (Cr) | |
| ₹40.00 | ₹40.00 | ₹36.50 | ₹37.90 | 4.07K (Cr) | |
| ₹36.06 | ₹38.85 | ₹33.16 | ₹36.71 | 3.48K (Cr) | |
| ₹36.45 | ₹36.78 | ₹33.15 | ₹36.24 | 7.42K (Cr) | |
| ₹33.00 | ₹34.15 | ₹32.01 | ₹34.00 | 2.35K (Cr) | |
| ₹31.00 | ₹34.00 | ₹31.00 | ₹33.89 | 9.51K (Cr) | |
| ₹32.00 | ₹32.00 | ₹31.50 | ₹31.50 | 500.00 (Cr) |
Parmax Pharma Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹37.03 | ₹41.00 | ₹37.00 | ₹40.67 | +9.83% | |
| ₹33.50 | ₹43.00 | ₹31.00 | ₹37.03 | +10.54% | |
| ₹31.90 | ₹35.93 | ₹27.45 | ₹30.02 | -5.89% | |
| ₹29.00 | ₹32.97 | ₹22.60 | ₹28.44 | -1.93% | |
| ₹34.71 | ₹39.99 | ₹29.00 | ₹30.20 | -12.99% | |
| ₹33.66 | ₹42.00 | ₹28.40 | ₹36.85 | +9.48% | |
| ₹35.49 | ₹35.89 | ₹29.08 | ₹33.83 | -4.68% | |
| ₹35.19 | ₹35.99 | ₹28.00 | ₹35.49 | +0.85% | |
| ₹31.33 | ₹35.68 | ₹29.30 | ₹34.37 | +9.70% | |
| ₹35.66 | ₹40.78 | ₹31.01 | ₹31.47 | -11.75% | |
| ₹36.31 | ₹40.00 | ₹34.11 | ₹35.49 | -2.26% | |
| ₹39.40 | ₹45.87 | ₹35.52 | ₹38.02 | -3.50% |
AI Research Briefing
Powered by Gemini · 2026-04-08
This micro-cap pharma is a value trap, not a turnaround story.
WHAT'S HAPPENING NOW
Parmax Pharma hit a 52-week low of around mid-March. Recent news includes the appointment of Ms. Bhakti Aghera as Company Secretary and Compliance Officer. No major catalysts found after live search.
CORE STORY
This is a micro-cap pharma stock trading on hope and hype, not current earnings. The market is likely pricing a turnaround or a significant contract win that hasn't materialized.
- Sector tailwinds
- Speculative micro-cap trading
- Unexpected large contract win
- Successful drug trial results
- Micro-cap liquidity risk
- Negative profitability and free cash flow
- Weak growth and deeply negative interest coverage
No FII or DII interest. Promoter holding stable [cite: brief].
Indian pharma sector has tailwinds, but Parmax is too small to benefit significantly.
No. Free Cash Flow 5Y: ₹-4.46 Cr [cite: brief]
Without a major catalyst, Parmax Pharma will likely continue to struggle. A cash infusion or significant order is needed to change the trajectory.
Primary Thesis Risk
Lack of profitability and liquidity could lead to collapse.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Parmax Pharma Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Parmax Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PARMAX across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Suboptimal ROCE (-12.45%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-845.45%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-72.74%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Interest Coverage (-3.55x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-4.46 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Parmax Pharma Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Parmax Pharma Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Parmax Pharma LtdParmax Pharma L...Selected✓ PARMAX • 540359 | 1.5/100 | ₹66.69₹67 | ₹12.83₹12.83 | — — | — — | -12.45%Poor -12.45% Poor | — — | — — | 6.15%Good 6.15% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Parmax Pharma Ltd Quarterly Performance
Latest quarterly metrics for PARMAX — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-72.74%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-845.45%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
6.15%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Parmax Pharma Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for PARMAX — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Parmax Pharma Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Parmax Pharma Ltd (PARMAX) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Parmax Pharma Ltd
About PARMAX (Parmax Pharma Ltd)
Parmax Pharma Ltd is a dynamic force in the pharmaceutical landscape, pushing the boundaries of chemical innovation and therapeutic solutions. Established with a vision to contribu...te to the well-being of society, Parmax focuses on the meticulous development and production of essential pharmaceutical ingredients. Situated in the heart of India's industrial hub, the company boasts state-of-the-art manufacturing facilities equipped with cutting-edge technology and staffed by a team of experienced scientists and engineers. Parmax Pharma's unwavering commitment to quality, safety, and environmental responsibility is reflected in its stringent adherence to global regulatory standards. The company's dedication extends beyond mere production; it is dedicated to fostering collaborative partnerships with researchers, healthcare providers, and other stakeholders to drive advancements in medical science. At the core of Parmax Pharma's operations lies a diverse portfolio of bulk drugs, advanced drug intermediates, and specialty chemicals, each meticulously crafted to meet the ever-evolving needs of the pharmaceutical industry. The company leverages its extensive research and development capabilities to formulate innovative products that address critical healthcare challenges. Parmax prioritizes sustainable manufacturing practices, ensuring that its operations are environmentally conscious and minimize their ecological footprint. This commitment to sustainability is deeply ingrained in the company's ethos, demonstrating its responsibility towards future generations. From the sourcing of raw materials to the final product release, Parmax Pharma maintains rigorous quality control measures to ensure the efficacy and safety of its offerings. Parmax Pharma stands as a testament to the power of Indian ingenuity and entrepreneurial spirit. From its humble beginnings, the company has steadily grown into a respected player in the global pharmaceutical market. Its success is built on a foundation of scientific excellence, ethical business practices, and a deep-seated commitment to customer satisfaction. Parmax Pharma's story is not just about manufacturing pharmaceuticals; it is about contributing to a healthier future for people around the world. With a clear vision and unwavering dedication, Parmax Pharma is poised to continue its journey of innovation and growth, solidifying its position as a trusted partner in the pursuit of better health.
Company Details
Key Leadership
Latest News
PARMAX Share Price: Frequently Asked Questions
What is the current share price of Parmax Pharma Ltd?
Parmax Pharma Ltd (PARMAX) trades at ₹66.69 on NSE and BSE. Market cap ₹12.83 (Cr). Educational data only.
What is the P/E ratio of Parmax Pharma Ltd?
Parmax Pharma Ltd has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for Parmax Pharma Ltd?
Parmax Pharma Ltd has a Bull Run score of 1.5/100 based on 25+ financial parameters.
Does Parmax Pharma Ltd pay dividends?
Parmax Pharma Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Parmax Pharma Ltd?
Parmax Pharma Ltd has ROE of N/A. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Parmax Pharma Ltd?
Parmax Pharma Ltd has debt-to-equity of N/A.
Is Parmax Pharma Ltd a good investment?
Bull Run gives Parmax Pharma Ltd a score of 1.5/100. This is not investment advice — consult a SEBI-registered advisor.